Company: DVAX
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001029142-25-000117
Chunk: 212

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 1
Chunk 212
---
 374 Net cash provided by (used in) operating activities3,792 (5,966)Investing activities    Purchases of marketable securities(111,793)(326,121)Proceeds from maturities and redemption of marketable securities218,875 301,713 Purchases of property and equipment, net(5,380)(1,528)Net cash provided by (used in) investing activities101,702 (25,936)Financing activities    Proceeds from issuance of Convertible Notes (Note 7)39,708 - Payment for debt issuance costs (Note 7)(4,500)- Payments for debt extinguishment (Note 7)(80,938)- Proceeds from unwind of capped call options (Note 7)46,554 - Payments for repurchase of common stock (Note 11)(100,635)- Proceeds from exercise of stock options6,738 2,054 Proceeds from Employee Stock Purchase Plan835 904 Payments for taxes related to net share settlement of restricted and performance stock units(11,562)(8,576)Net cash used in financing activities(103,800)(5,618)Effect of exchange rate changes on cash and cash equivalents, and restricted cash1,558 (265)Net increase (decrease) in cash and cash equivalents, and restricted cash3,252 (37,785)Cash and cash equivalents, and restricted cash at beginning of period96,154 150,556 Cash and cash equivalents, and restricted cash at end of period$99,406 $112,771 Supplemental disclosure of cash flow information    Cash paid during the period for income taxes$2,150 $2,963 Cash paid during the period for interest$2,021 $2,819 Non-cash investing and financing activities:    Purchases of property and equipment, not yet paid$1,700 $574 See accompanying notes.

8

Dynavax Technologies Corporation 

Notes to Condensed Consolidated Financial Statements 

(Unaudited) 

1. Organization

Dynavax Technologies Corporation (“we,” “our,” “us,” “Dynavax” or the “Company”) is a commercial stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. Our first marketed product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adju